References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492
- Frezzetti D, Gallo M, Maiello MR, D’Alessio A, Esposito C, Chicchinelli N, Normanno N, De Luca A. VEGF as a potential target in lung cancer. Expert Opin Ther Targets. 2017;21(10):959–66. doi:https://doi.org/10.1080/14728222.2017.1371137
- Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19(1):279–90.:doi:https://doi.org/10.1158/1078-0432.CCR-12-1558
- Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, Hafeez N, Bilton SJ, Drier Y, Ji F, et al. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 2019;38(37):6399–413.:doi:https://doi.org/10.1038/s41388-019-0887-2
- Gullick WJ. The Type 1 growth factor receptors and their ligands considered as a complex system. Endocr Relat Cancer. 2001;8(2):75–82. doi:https://doi.org/10.1677/erc.0.0080075
- Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001;8(1):11–31. doi:https://doi.org/10.1677/erc.0.0080011
- Kim H, Kim S-H, Kim M-J, Kim S-J, Park S-J, Chung J-S, Bae J-H, Kang C-D. EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother. 2011;34(4):372–81. doi:https://doi.org/10.1097/CJI.0b013e31821b724a
- Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 2011;3(3):192–222.:doi:https://doi.org/10.18632/aging.100296
- Ju L, Shan L, Yin B, Song Y. Delta-Catenin regulates proliferation and apoptosis in renal cell carcinoma via promoting beta-catenin nuclear localization and activating its downstream target genes. Cancer Med. 2020;9(6):2201–12. doi:https://doi.org/10.1002/cam4.2857
- Vilgelm AE, Richmond A. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. Front Immunol. 2019;10:333. doi:https://doi.org/10.3389/fimmu.2019.00333
- Ouh Y-T, Cho HW, Lee JK, Choi SH, Choi HJ, Hong JH. CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer. Tumour Biol. 2019;42(4):1010428319842699 doi:https://doi.org/10.1177/1010428319842699
- Palacios-Arreola MI, Nava-Castro KE, Castro JI, García-Zepeda E, Carrero JC, Morales-Montor J. The role of chemokines in breast cancer pathology and its possible use as therapeutic targets. J Immunol Res. 2014;2014:849720 doi:https://doi.org/10.1155/2014/849720
- Lakka SS, Bhattacharya A, Mohanam S, Boyd D, Rao JS. Regulation of the uPA gene in various grades of human glioma cells. Int J Oncol. 2001;18(1):71–9.
- Noh H, Hong S, Huang S. Role of urokinase receptor in tumor progression and development. Theranostics. 2013;3(7):487–95. doi:https://doi.org/10.7150/thno.4218
- Gach K, Wyrebska A, Szemraj J, Janecka A. The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines. Mol Biol (Mosk). 2012;46(6):894–9.
- Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6(4):121–5. doi:https://doi.org/10.1016/0168-9525(90)90126-q
- Zhu X, Chen L, Liu L, Niu X. EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies. Front Oncol. 2019;9:1044. doi:https://doi.org/10.3389/fonc.2019.01044
- Nurwidya F, Takahashi F, Murakami A, Takahashi K. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat. 2012;44(3):151–6. doi:https://doi.org/10.4143/crt.2012.44.3.151
- Dinglin X, Ding L, Li Q, Liu Y, Zhang J, Yao H. RYBP inhibits progression and metastasis of lung cancer by suppressing EGFR signaling and epithelial-mesenchymal transition. Transl Oncol. 2017;10(2):280–7. doi:https://doi.org/10.1016/j.tranon.2017.01.004
- She K, Fang S, Du W, Fan X, He J, Pan H, Huang L, He P, Huang J. SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals. Cancer Cell Int. 2019;19:103 doi:https://doi.org/10.1186/s12935-019-0809-y
- Greenlee H. Natural products for cancer prevention. Semin Oncol Nurs. 2012;28(1):29–44. doi:https://doi.org/10.1016/j.soncn.2011.11.004
- Formica JV, Regelson W. Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol. 1995;33(12):1061–80. doi:https://doi.org/10.1016/0278-6915(95)00077-1
- Bischoff SC. Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care. 2008;11(6):733–40. doi:https://doi.org/10.1097/MCO.0b013e32831394b8
- Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269(2):315–25. doi:https://doi.org/10.1016/j.canlet.2008.03.046
- Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu Y-L, Paz-Ares L.Jr. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi:https://doi.org/10.1016/S0140-6736(16)30958-8
- Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156–9. doi:https://doi.org/10.1006/abio.1987.9999
- Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8. doi:https://doi.org/10.1038/nprot.2008.73
- Hashemzaei M, Far AD, Yari A, Heravi RE, Tabrizian K, Taghdisi SM, Sadegh SE, Tsarouhas K, Kouretas D, Tzanakakis G, et al. Anticancer and apoptosisinducing effects of quercetin in vitro and in vivo. Oncol Rep. 2017;38(2):819–28. doi:https://doi.org/10.3892/or.2017.5766
- Dong Y, Yang J, Yang L, Li P . Quercetin inhibits the proliferation and metastasis of human non-small cell lung cancer cell line: the key role of Src-mediated fibroblast growth factor-inducible 14 (Fn14)/ nuclear factor kappa B (NF-κB) pathway . Med Sci Monit. 2020;26:e920537 doi:https://doi.org/10.12659/MSM.920537
- Xingyu Z, Peijie M, Dan P, Youg W, Daojun W, Xinzheng C, Xijun Z, Yangrong S. Quercetin suppresses lung cancer growth by targeting Aurora B kinase. Cancer Med. 2016;5(11):3156–65. doi:https://doi.org/10.1002/cam4.891
- Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda). 2010;25(2):85–101. doi:https://doi.org/10.1152/physiol.00045.2009
- Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hauptmann M, de Visser KE, van den Heuvel MM, Linn SC. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(12):1939–48. doi:https://doi.org/10.1097/JTO.0b013e3181f77a39
- Kennedy SG, Wagner AJ, Conzen SD, Jordán J, Bellacosa A, Tsichlis PN, Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 1997;11(6):701–13. doi:https://doi.org/10.1101/gad.11.6.701
- Hseu Y-C, Lin Y-C, Rajendran P, Thigarajan V, Mathew DC, Lin K-Y, Way T-D, Liao J-W, Yang H-L . Antrodia salmonea suppresses invasion and metastasis in triple-negative breast cancer cells by reversing EMT through the NF-κB and Wnt/β-catenin signaling pathway. Food Chem Toxicol. 2019;124:219–30. doi:https://doi.org/10.1016/j.fct.2018.12.009
- Zhang C, Su L, Huang L, Song ZY . GSK3β inhibits epithelial-mesenchymal transition via the Wnt/β-catenin and PI3K/Akt pathways. Int J Ophthalmol. 2018;11(7):1120–8. doi:https://doi.org/10.18240/ijo.2018.07.08
- Cheng Z-H, Shi Y-X, Yuan M, Xiong D, Zheng J-H, Zhang Z-Y. Chemokines and their receptors in lung cancer progression and metastasis. J Zhejiang Univ Sci B. 2016;17(5):342–51. doi:https://doi.org/10.1631/jzus.B1500258
- Schadendorf D, Möller A, Algermissen B, Worm M, Sticherling M, Czarnetzki B. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol. 1994;153:3360.
- Wu S, Singh S, Varney ML, Kindle S, Singh RK. Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis. Cancer Med. 2012;1(3):306–17. doi:https://doi.org/10.1002/cam4.28
- Mauro CD, Pesapane A, Formisano L, Rosa R, D’Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Monteleone F, et al. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci Rep. 2017;7(1):9388:doi:https://doi.org/10.1038/s41598-017-10062-1
- Senthilkumar K, Arunkumar R, Elumalai P, Sharmila G, Gunadharini DN, Banudevi S, Krishnamoorthy G, Benson CS, Arunakaran J. Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct. 2011;29(2):87–95. doi:https://doi.org/10.1002/cbf.1725
- Chang J-H, Lai S-L, Chen W-S, Hung W-Y, Chow J-M, Hsiao M, Lee W-J, Chien M-H. Quercetin suppresses the metastatic ability of lung cancer through inhibiting Snail-dependent Akt activation and Snail-independent ADAM9 expression pathways. Biochim Biophys Acta Mol Cell Res. 2017;1864(10):1746–58. doi:https://doi.org/10.1016/j.bbamcr.2017.06.017
- Jechlinger M, Grunert S, Tamir IH, Janda E, Lüdemann S, Waerner T, Seither P, Weith A, Beug H, Kraut N, et al. Expression profiling of epithelial plasticity in tumor progression. Oncogene. 2003;22(46):7155–69.:doi:https://doi.org/10.1038/sj.onc.1206887
- Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54. doi:https://doi.org/10.1038/nrc822
- Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. Faseb J. 2010;24(6):1838–51. doi:https://doi.org/10.1096/fj.09-151639
- Huang DY, Dai ZR, Li WM, Wang RG, Yang SM . Inhibition of EGF expression and NF-κB activity by treatment with quercetin leads to suppression of angiogenesis in nasopharyngeal carcinoma . Saudi J Biol Sci. 2018;25(4):826–31. doi:https://doi.org/10.1016/j.sjbs.2016.11.011
- Lin T-H, Hsu W-H, Tsai P-H, Huang Y-T, Lin C-W, Chen K-C, Tsai I-H, Kandaswami CC, Huang C-J, Chang G-D, et al. Dietary flavonoids, luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial-mesenchymal transition signaling. Food Funct. 2017;8(4):1558–68.:doi:https://doi.org/10.1039/c6fo00551a
- Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 1999;20(5):749–55. doi:https://doi.org/10.1093/carcin/20.5.749
- Merchant N, Nagaraju GP, Rajitha B, Lammata S, Jella KK, Buchwald ZS, Lakka SS, Ali AN. Matrix metalloproteinases: their functional role in lung cancer. Carcinogenesis. 2017;38(8):766–80. doi:https://doi.org/10.1093/carcin/bgx063
- Wurtz SO, Schrohl AS, Mouridsen H, Brunner N . TIMP-1 as a tumor marker in breast cancer-an update. Acta Oncol. 2008;47(4):580–90. doi:https://doi.org/10.1080/02841860802022976
- Wang W, Li D, Xiang L, Lv M, Tao L, Ni T, Deng J, Gu X, Masatara S, Liu Y, et al. TIMP-2 inhibits metastasis and predicts prognosis of colorectal cancer via regulating MMP-9. Cell Adh Migr. 2019;13(1):273–84. doi:https://doi.org/10.1080/19336918.2019.1639303